Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 299

Sort by

Sort Order Select

Journal Articles

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Blood (2019) 134 (Supplement_1): 911.

https://doi.org/10.1182/blood-2019-125007

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Fumihiko Nakao, MD, Takuji Yamauchi, MD PhD, Yuichiro Semba, MD PhD, Jumpei Nogami, PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 912.

https://doi.org/10.1182/blood-2019-129237

Published: 2019

Journal Articles

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Danielle Canioni, MD, Josquin Moraly, MD, Ludovic Lhermitte, MD PhD, Laura Polivka, MD, Mélanie Féroul, Julien Rossignol, MD PhD, Laurent Frenzel, MD PhD, Michel Arock, pharmD, PhD, Patrice Dubreuil, PhD, Leila maouche-Chretien, PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 1683.

https://doi.org/10.1182/blood-2019-131256

Published: 2019

Journal Articles

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 258.

https://doi.org/10.1182/blood-2019-126172

Published: 2019

Journal Articles

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia

Seth E Karol, MD, Thomas Alexander, MDMPH, Amit Budraja, PhD, Stanley Pounds, PhD, Kristin E Canavera, PhD, Lei Wang, MS, Joshua Wolf, MBBS, PhD, Jeffery M. Klco, MD PhD, Ahmed Hamed Salem, PhD FCP, Tammy Palenski, PhD, Norman J. Lacayo, MD, Ching-Hon Pui, MD, Joseph T. Opferman, PhD, Jeffrey Rubnitz, MD PhD

Blood (2019) 134 (Supplement_1): 178.

https://doi.org/10.1182/blood-2019-127716

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

Arsenic Trioxide Upregulates Cereblon mRNA Expression and Potentiates Sensitivity of SKM-1 and MDS-L Cells to Lenalidomide

Radka Bokorová, Ota Fuchs, PhD, Denisa Myslivcova, PhD, Jaroslav Cermak

Blood (2019) 134 (Supplement_1): 5397.

https://doi.org/10.1182/blood-2019-126443

Published: 2019

Journal Articles

Desialylation and Apoptosis Crosstalk to Modulate Platelet Clearance

Renata Grozovsky, PhD, Cameron Fraser, BS, Karin M. Hoffmeister, MD, Kristopher Sarosiek, PhD, Silvia Giannini, PhD

Blood (2019) 134 (Supplement_1): 1055.

https://doi.org/10.1182/blood-2019-122184

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Blood (2019) 134 (Supplement_1): 807.

https://doi.org/10.1182/blood-2019-126773

Published: 2019

Journal Articles

Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 286.

https://doi.org/10.1182/blood-2018-99-113749

Published: 2018

Journal Articles

Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1

Elsa Sanchez-Lopez, PhD, Emanuela M. Ghia, PhD, Laura Antonucci, PhD, Laura Z. Rassenti, PhD, Yun Chen, PhD, Thomas J. Kipps, MD PhD, Michael Karin, PhD

Blood (2018) 132 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2018-99-115564

Published: 2018

Journal Articles

A Novel Cycs Missense Mutation in the α-Helix of the Cycs C-Terminal Domain Causes Non-Syndromic Thrombocytopenia

Yuri Uchiyama, MD PhD, Kunio Yanagisawa, MD PhD, Shinji Kunishima, PhD, Masaaki Shiina, MD PhD, Yoshiyuki Ogawa, MD PhD, Mitsuko Nakashima, MD PhD, Satoko Miyatake, MD PhD, Satomi Mitsuhashi, MD PhD, Atsushi Takata, MD PhD, Noriko Miyake, MD PhD, Kazuhiro Ogata, MD PhD, Hiroshi Handa, MD PhD, Naomichi Matsumoto, MD PhD, Takeshi Mizuguchi, MD PhD

Blood (2018) 132 (Supplement 1): 3758.

https://doi.org/10.1182/blood-2018-99-114729

Published: 2018

Journal Articles

Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia

Jacqueline S Garcia, MD, Shruti Bhatt, PhD, Geoffrey Fell, PhD, Traci M. Blonquist, MS, Jack Taw, David Iberri, MD, Anthony Letai, MD PhD, Bruno C. Medeiros, MD

Blood (2018) 132 (Supplement 1): 4058.

https://doi.org/10.1182/blood-2018-99-117428

Published: 2018

Journal Articles

Interferon-Gamma Induced Changes in Gene Expression Dramatically Alter Neutrophil Phenotype

Michael Ellison, PhD, Natalie Briones, MS, Angelina Baroffio, John Murphy, Katherine Gowan, Bridget Sanford, Kenneth L. Jones, PhD, Daniel R. Ambruso, MD

Blood (2018) 132 (Supplement 1): 2398.

https://doi.org/10.1182/blood-2018-99-115314

Published: 2018

Journal Articles

Effects of Interferon-Gamma 1-b (IFN-Î³) on Neutrophil Function and Biochemistry in Patients with Chronic Granulomatous Disease

Daniel R. Ambruso, MD, Michael Ellison, PhD, Natalie Briones, MS, Alexander Tran, MS

Blood (2018) 132 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2018-99-115683

Published: 2018

Journal Articles

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Rebecca Valentin, MD, Marisa O. Peluso, MS, Timothy Z. Lehmberg, BA, Ammar Adam, DVM, Li Zhang, MA, Caroline M. Armet, BS, Jennifer L. Guerriero, PhD, Benjamin H. Lee, MD PhD, Vito J. Palombella, PhD, Pamela M. Holland, PhD, Alison M. Paterson, PhD, Matthew S. Davids, MD

Blood (2018) 132 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2018-99-110181

Published: 2018

Journal Articles

ABT-199 (venetoclax) Synergizes Cytotoxicity of Cytotoxic T-Cell (CTL) to B-Cell Lymphomas

Satsuki Murakami, MD, Susumu Suzuki, PhD, Ichiro Hanamura, MD PhD, Kazuhiro Yoshikawa, PhD, Ryuzo Ueda, MD PhD, Akiyoshi Takami, MD

Blood (2018) 132 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2018-99-117471

Published: 2018

Journal Articles

Overcoming MCL1 Resistance in Multiple Myeloma

Ka Tat Siu, PhD, Cherrie Huang, Cristina Panaroni, PhD, Kenta Mukaihara, MD PhD, Keertik Fulzele, PhD, Rosemary Soucy, Justin Cidado, PhD, Lisa Drew, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 472.

https://doi.org/10.1182/blood-2018-99-116377

Published: 2018

Journal Articles

Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action

Sergei Vatolin, PhD, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 1302.

https://doi.org/10.1182/blood-2018-99-114838

Published: 2018

NARROW

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Arsenic Trioxide Upregulates Cereblon mRNA Expression and Potentiates Sensitivity of SKM-1 and MDS-L Cells to Lenalidomide

Desialylation and Apoptosis Crosstalk to Modulate Platelet Clearance

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1

A Novel Cycs Missense Mutation in the α-Helix of the Cycs C-Terminal Domain Causes Non-Syndromic Thrombocytopenia

Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia

Interferon-Gamma Induced Changes in Gene Expression Dramatically Alter Neutrophil Phenotype

Effects of Interferon-Gamma 1-b (IFN-Î³) on Neutrophil Function and Biochemistry in Patients with Chronic Granulomatous Disease

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

ABT-199 (venetoclax) Synergizes Cytotoxicity of Cytotoxic T-Cell (CTL) to B-Cell Lymphomas

Overcoming MCL1 Resistance in Multiple Myeloma

Novel Small Molecule Stimulants of Hematopoietic Stem Cells and Their Mode of Action

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only